REFERENCES
  1. Allan F, Guthrie B, Kelman A. Polypharmacy: a framework for theory and practice. Pharm J 2019 303: 324-331. https://www.pharmaceutical-journal.com/cpd-and-learning/cpd-article/polypharmacy-a-framework-for-theory-and-practice/20207246.cpdarticle?
  2. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004 329:15-19 https://doi:10.1136/bmj.329.7456.15.
  3. Multimorbidity and polypharmacy. NICE key therapeutics topic (KTT18). 2017. : https://www.nice.org.uk/advice/ktt18. Accessed July 2020.
  4. Murshid MA and Mohaidin Z. Models and theories of prescribing decisions: A review and suggested new model. Pharm Pract (Granada) 2017 15 2:990. https://doi:10.18549/PharmPract.2017.02.990
  5. Stros M and Lee N. Marketing dimensions in the prescription pharmaceutical industry: a systematic literature review. J Strategic Mark. 2015;23 (4):318-336. https://doi.org/10.1080/0965254X.2014.931878. Accessed July 2020.
  6. Kyle GJ et al. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines. J Clin Pharm Ther 2008;33(5):553-559. https://doi.org/10.1111/j.1365-2710.2008.00948.x. Accessed July 2020.
  7. A patient-centred approach to polypharmacy. NHS Specialist Pharmacy Service. 2017. : https://www.sps.nhs.uk/articles/polypharmacy-oligopharmacy-deprescribing-resources-to-support-local-delivery/ Accessed January 4, 2020.
  8. Duerden M et al. Polypharmacy and medicines optimisation: making it safe and sound. The King’s Fund. 2013. : https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf. Accessed July 2020.
  9. Royal Pharmaceutical Society. Polypharmacy: Getting our medicines right. 2019. https://www.rpharms.com/recognition/setting-professional-standards/polypharmacy-getting-our-medicines-right. Accessed July 2020.
  10. Polypharmacy guidance: realistic prescribing. 3rdEdn. 2018. Scottish government. : https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/04/Polypharmacy-Guidance-2018.pdf. Accessed July 2020.
  11. Polypharmacy: guidance for prescribing. All Wales Medicines Strategy Group. 2014. : http://awmsg.org/docs/awmsg/medman/Polypharmacy%20-%20Guidance%20for%20Prescribing.pdf. Accessed July 2020.
  12. American Geriatrics Society Beers criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019:67(4):674-694. https://doi.org/10.1111/jgs.15767.
  13. O’Mahony D, O’Sullivan D, Byrne S,  O’Connor MN, Ryan C, Gallagher G. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2: Age Ageing 2015;44 (2): 213-218. https://doi.org/10.1093/ageing/afu145
  14. O’Mahony D, Gudmundsson A, Soiza RL, et al. Prevention of adverse reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR randomized controlled trial. Age Ageing 2020;1 https://doi.org/10.1093/ageing/afaa072.
  15. Aronson JA pragmatic view of thematic analysis 1995. The Qualitative Report, 2 (1), 1-3. https://nsuworks.edu/tqr/vol2/iss1/3.
  16. Outhwaite W.1975. Understanding Social Life: The Method Called Verstehen. London: George Allen Unwin.
  17. Symon G & Cassell C (2012). Qualitative Organizational Research: Core Methods and Current Challenges. Sage, London. 20 p.
  18. Patwardhan AR. Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest: Challenges and Solutions. The Journal of Health Care Organization, Provision, and Financing 2016 53: 1-5. https://doi.org/10.1177/0046958016667597.
  19. Royal Pharmaceutical Society 2015. Medicines Reconciliation: Best practice Resource and Toolkit. https://www.sps.nhs.uk/articles/medicines-reconciliation-best-practice-resource-and-toolkit. Accessed July 2020.
  20. Anderson C et al. Feedback from community pharmacy users on the contribution of community pharmacy to improving the public’s health: a systematic review of the peer reviewed and non-peer reviewed literature 1990-2002. Health Expect 2004 7 (3):191-202. https://doi.org/10.1111/j.1369-7625.2004.00274.x
  21. Tan ECK, Stewart K, Elliott RA, Johnson G. Pharmacist consultation in general practice clinics: The Pharmacists in Practice Study. Res Social Adm Pharm 2014 10: 623-632. https://doi.org/10.1016/j.sapharm.2013.08.005.
  22. Rivers PH, Waterfield J, Grootveld M. Exploring the prevalence of and factors associated with advice on prescription medicines: a survey of community pharmacies in an English city. Health Soc Care Comm 2017:25(6):1774-1786. https://doi.org/10.1111/hsc.12451.
  23. Din R, Sardar CM, Bryson G, McGarry V. Evaluation of a pharmacist-led polypharmacy review project 2020. Pharm J 304: 340-347. https://doi.org/10.1211/PJ.2020.20207920.
  24. Wilcock M, Sibley A, Blackwell R, Kluettgens B, Robens S, Bastian L. Involving community pharmacists in transfer of care from hospital: Indications of a reduced 30-day hospital readmission rates for patients in Cornwall. Int.J Pharm Prac 2020 28 (1). https://doi.org/10.1111/ijpp.12603.
  25. Olowagbemileke O, Avery A, Gupta A, Boyd M. The evidence for the effectiveness of safety alerts in electronic patient medication record systems at the point of pharmacy order entry: a systematic review. BMC Med Inform Decis 201313: 69. http://www.biomedcentral.com/1472-6947/13/69.
  26. Lewis PJ, Tully MP. The discomfort caused by patient pressure on the prescribing decisions of hospital prescribers 2011 Res Soc Adm Pharm 7: 4-15. https://doi.org/10.1258/jrsm.2009.090150.
  27. Slight SP, Howard R, Ghaleb M et al.The causes of prescribing errors in English general practices: a qualitative study Br J Gen Pract 2013; 63 (615) e713-e720. https://doi.org/10.3399/bjgp13X673739.
  28. Primary Care Delivery: Policy & Strategy, Operations & Information Directorate NHS England Responsibility for prescribing between Primary & Secondary/Tertiary Care: January 2018: : https://www.england.nhs.uk/wp-content/uploads/2018/03/responsibility-prescribing-between-primary-secondary-care-v2.pdf). Accessed July 2020.
  29. Hill-Taylor B, Sketris I, Hayden J, Byrne S, OSullivan D, Christie R. Application of STOPP/START criteria: a systematic review of the prevalence of inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther 2013 38 (5):360-372. https://doi.org/10.1111/jcpt.12059.
  30. Verdoorn S, Kwint HF, Hoogland P, Gussekloo MD, Bouvy ML. Drug related problems identified during medication review before and after the introduction of a clinical decision support system. J Clin Pharm Ther 2017 43: 224 – 231. https://doi.org/10.1111/jcpt.12637.
  31. Meulendijk MC, Spruit MR, Drenth-van Maanen AC et al. Computerized decision support improves medication review effectiveness: an experiment evaluating the STRIP Assistant’s usability. Drugs Aging 2015 32: 495-503. https://doi.org/10.1007/s40266-015-0270-0
  32. Monteiro C, Canario C, Ribeiro MA, Duarte AP, Alves G. Medication evaluation in Portuguese elderly patients according to Beers, STOPP/START criteria and EU (7)-PIM List – An Exploratory Study 2020 Patient Prefer Adher 14: 795-802. doi:10.2147/PPA.S247013.
  33. Thomas RE. Assessing medication problems in those >65 using the STOPP and START criteria. Current Aging Science 2016 9: 150-159 http://doi.org/10.2174/1874609809999160217101716.